Resources
21 Results (showing 1 - 10)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 11/19/2019 (updated 3/28/2024)
Posted 3/19/2020 (updated 3/28/2024)
To help local leaders respond to this epidemic, USDA has worked to build infrastructure for prevention, treatment and recovery, facilitate partnerships, and drive innovation in rural communities.
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Monument Room on Wednesday, March 4, 2020, at 4:15 PM
Posted 4/6/2020 (updated 3/28/2024)
Opioid overdose death rates were reduced in communities where overdose education and nasal naloxone distribution (OEND) was implemented. This study provides observational evidence that by training potential bystanders to prevent, recognize, and respond to opioid overdoses, OEND is an effective intervention.
Posted 8/11/2020 (updated 4/2/2024)
Non-fatal opioid overdose (NFOO) is a significant cause of opioid-related morbidity in the United States. As the number of NFOOs continues to grow, it is important to understand the short- and long-term consequences of NFOO. This report examines the existing literature on the acute and chronic health and functional outcomes of individuals who experience NFOO, and also identifies differences in outcomes for NFOOs involving illicitly-manufactured fentanyl.
Posted 9/22/2020 (updated 3/29/2024)
The Post-Overdose Response (PORT) Toolkit was developed as a resource for North Carolina communities who are interested in creating a post-overdose response team (PORT) in their jurisdiction.
Posted 10/13/2020 (updated 3/27/2024)
The CDC’s National Vital Statistics System has been updated to now include data related to February 2020 overdose mortality, with trends indicating further worsening of the nation’s opioid epidemic.
Posted 5/26/2021 (updated 4/10/2024)
Opioid dependence is a chronic relapsing disorder with considerable individual and global public health burden. The current standard of care for opioid dependence includes treatment with methadone or sublingual (SL) buprenorphine or buprenorphine-naloxone (hereafter, buprenorphine), combined with psychosocial and behavioral support. Both medications are associated with reductions in mortality, illicit opioid use, bloodborne viral infections, and criminal behavior as well as better cost-effectiveness than no treatment or psychosocial treatment alone. Buprenorphine is a partial μ-opioid receptor agonist, enabling office-based treatment for nonsupervised or take-home use of the medication. However, SL formulations of buprenorphine are prone to nonmedical use (eg, injecting, diversion), prompting models of care, particularly in the early phases of treatment, requiring regular attendance at clinics or pharmacies for administration of doses.
Posted 6/17/2021 (updated 4/2/2024)
Fueled by misinformation, fentanyl panic has harmed public health through complicating overdose rescue while rationalizing hyper-punitive criminal laws, wasteful expenditures, and proposals to curtail vital access to pain pharmacotherapy. To assess misinformation about health risk from casual contact with fentanyl, we characterize its diffusion and excess visibility in mainstream and social media.
Posted 8/4/2021 (updated 4/2/2024)
This program brief highlights the Alliance for Prevention and Wellness (APW) use of Overdose Detection Mapping Application Program (ODMAP) data to target a broad range of substance use prevention and education activities to ZIP codes with the highest rate of overdoses. Source: Bureau of Justice Assistance (BJA)-Supported Comprehensive Opioid, Stimulant, and Substance Abuse Program (COSSAP).